Fruzaqla® (fruquintinib)
for Colorectal Cancer
Fruzaqla (fruquintinib) is an oral kinase inhibitor used to treat metastatic colorectal cancer (mCRC) in adults who previously received chemotherapy and targeted treatments. It selectively inhibits VEGFR-1, -2, and -3, blocking tumor angiogenesis—the formation of new blood vessels that supply tumors with oxygen and nutrients for growth. Fruzaqla’s high selectivity enhances its effectiveness while minimizing effects on other receptors, making it a potential option for combination therapy.
